Multiple Sclerosis
Conference Coverage
High-Dose Vitamin D Linked to Lower Disease Activity in CIS
The 34% reduction in relative risk for disease activity is “similar to that of some published platform therapies for CIS patients.”
Conference Coverage
Positive Stem Cell Transplant Data Is Increasing Its Use
The growing quantity of real-world data supporting hematopoietic stem cell transplant for MS is driving its growing routine application at centers...
Conference Coverage
Comorbidity Control Might Slow MS Activity
FDA/CDC
FDA Okays Subcutaneous Ocrelizumab for MS
The subcutaneous (SC) injection can be administered by a healthcare professional in approximately 10 minutes and is the first and only twice-a-...
Literature Review
Does MS Protect Against Alzheimer’s Disease?
Understanding how MS may protect patients from Alzheimer’s disease may drive new treatment strategies.
News
EMA Warns of Anaphylactic Reactions to MS Drug
Glatiramer acetate is associated with a risk for anaphylactic reactions, which may occur shortly after administration or even months or years...
Literature Review
COMBAT-MS: Therapy Choice for Relapsing-Remitting MS Has ‘Small’ Impact on Disability Progression, Patient-Reported Outcomes
The decision to start or switch a therapy for relapsing-remitting multiple sclerosis did not significantly impact disability progression, but...
Recap
Anti-CD20 Therapy for Relapsing Multiple Sclerosis
Dr Fred Lublin reviews recent data on anti-CD20 therapies for patients with relapsing multiple sclerosis focusing on dosing intervals, infection...
Conference Coverage
Shift Needed in Research, Treatment, Care for Aging MS Population
Independent of disease progression, the impact of aging on MS has been underappreciated in research and in clinical practice.
Conference Coverage
Prospective MS Trial Proves Ocrelizumab Efficacy in Under-Represented Populations
A prospective phase 4 clinical trial that recruited solely Black and Hispanic patients could shed light on divergent treatment outcomes.
Conference Coverage
Pediatric Ocrelizumab Dose Established for MS
Pharmacokinetic and pharmacodynamic data show that adult dose is safe and effective for most children.